Team:Nottingham/Project
Description
Clostridium difficile
Clostridium difficile is a Gram-positive, rod-shaped, anaerobic bacterium and is the most common causative agent of hospital-acquired diarrhoea in the Western world. The symptoms of C. difficile infection (CDI) can range from watery diarrhoea to pseudomembranous colitis, toxic megacolon and in severe cases death. Most C. difficile strains produce two major toxins, TcdA and TcdB, which are responsible for causing the characteristic symptoms of CDI.
C. difficile is estimated to be present in the natural gut microbiota of around 4% of the healthy adult population however, exposure to broad-spectrum antibiotics, such as cephalosporins, can cause disruption to the microbiota. This disruption can promote the colonisation of toxigenic strains allowing infection to persist. It is thought that non-toxigenic strains of C. difficile can act as a probiotic by outcompeting toxigenic strains in the gut and reducing the likelihood of disease. Currently, CDI is treated using two main antibiotics, metronidazole and vancomycin however, raised concerns over the emergence of antibiotic resistance has led to a desire for alternative treatments.
Phage and phage therapy
Bacteriophages (phages) are viruses which infect bacteria and can exist anywhere bacteria are located. Phages are highly specific, only infecting a single species or strain of bacteria and can be defined as either lytic or temperate depending on the life cycle they follow.
Lytic phages exclusively follow the lytic lifecycle, following infection these phages will hijack the host cell machinery to produce multiple copies of the phage proteins. These proteins are then assembled into multiple phage progeny which burst out of the host cell and go onto infect other bacterial cells. Temperate phages can follow the lytic life cycle but are also able to follow the lysogenic life cycle. These phages can integrate their genome in the host cell chromosome upon infection where they can remain dormant for long periods of time as prophages. When conditions are favourable, usually due to host cell stress, these prophages can excise from the host cell chromosome and enter the lytic life cycle where progeny phage particles are produced. To date, all phages found to infect C. difficile are temperate phages.
Ever since the first phage was isolated their use as a potential therapeutic agent has been explored, such as in the treatment of wound infections. Traditionally such therapy relies on strictly lytic phages to wipe out the problematic/problem causing bacterial populations. Phage therapy would be an ideal alternative treatment for CDI as their highly specific nature would mean they would not disrupt the natural gut microbiota, only targeting C. difficile cells.
This could reduce the incidence of relapse by allowing the gut microbiota to remain in its protective role against future colonisation. In comparison to antibiotics, the impact of resistance to phage therapy would be minimal due to phages and bacteria co-evolving. As bacteria gain resistance to overcome phage infection, the phages can evolve to evade these systems resulting in susceptible bacterial populations which can be treated. Although phage therapy would be the ideal alternative treatment for CDI the major roadblock is that no strictly lytic phages currently exist.
Project description
The main aim of this project was to create a therapeutic for CDI that would allow the natural gut microbiota to remain unchanged and reduce the reliance on antibiotics. To achieve this goal phage therapy was selected as an appropriate alternative due to its highly specific nature. It has been shown that non-toxigenic strains of C. difficile can act as probiotics to reduce the colonisation of toxigenic C. difficile in the gut therefore, by silencing the toxin gene expression in C. difficile, non-toxigenic probiotic strains are created.
Abstract
Antibiotics serve a critical role in remedying bacterial infections, however a major disadvantage to their use is the non-specificity of broad spectrum antibiotics that drastically kills off beneficial bacteria reducing the diversity of the gut flora. The use of antibiotics allows opportunistic pathogens like Clostridium difficile to take advantage of the dysbiosis caused.
A consequence of antibiotic misuse and the capability of bacteria to readily adapt to versatile conditions, has allowed antibiotic resistance in bacteria to become a major dilemma. Each year in the United States alone 2 million people are subject to infection from antibiotic resistant bacteria. Phage therapy is an alternative to antibiotics. The goal of our project was to engineer a bacteriophage which will infect C. difficile and express genetic constructs designed to suppress toxin production. We will pursue two strategies to achieve this; asRNA and dCAS-9, both of which will target the toxin genes tcdB and tcdA. Ultimately, we aim to produce a phage therapy which will reduce toxigenicity of resident strains of C. difficile without significantly affecting the native gastrointestinal microbiota.
Project description
What is ClostridiumdTOX?
Clostridium dTOX is the University of Nottingham 2018 iGEM project that aims to engineer a lysogenic bacteriophage with genetic constructs that will suppress the toxin production in Clostridium difficile, an anaerobic bacterium that causes hospital-and community-acquired diarrhoea. We will be using two different strategies to target C. difficile toxins: an antisense RNA system capable of inhibiting translation of toxin transcripts, and a dead Cas9 mechanism to inhibit transcription of the toxin genes. Each method will use different genetic constructs which perform different roles to ultimately decrease toxin production. In the climate of antibiotic resistance, our goal is to produce a specific, novel phage therapy that not only will reduce C. difficile virulence but will be easy to administer and is more affordable than current treatments. For more information on why we chose to tackle C. difficile infection, please see our abstract. For more information on phage therapy, please visit our ‘Human Practices Gold’ page. For more information on the impact of C. difficile infection and how our project will influence society, please visit our ‘Human Practices Silver’ page.
Antisense RNA
The use of antisense RNA is demonstrated in both pro-and eukaryotes but it is best documented inplants. Post-transcriptional gene silencing is an epigenetic processutilised by plants, fungi and animals to target cellular and viral RNA. Plants target viral RNA with antisense RNA as an immunological defence mechanism against viral infection (Hamilton and Baulcombe, 1999). Upon encountering viral RNA, the complementary antisense RNA strand binds it, forming a double stranded RNA molecule which speeds up the (RNA) degradation process and inhibits ribosomal binding (hence the initiation of translation).As a result, RNA interference has been exploited as a technology for identifying gene function through inhibition of gene expression (Vaucheret, Béclin and Fagard, 2001; Hammond, Caudy and Hannon, 2001). For more information on why we chose antisense RNA specifically and on how we plan to use it, please visit our ‘Antisense RNA’ page.
More informationDead Cas9
Discovered as a bacterial defence mechanism against viral infection, the CRISPR-Cas system has revolutionised the field of synthetic biology and made gene editing cheaper, faster and easier (Schmidt and Platt, 2017; Sander and Joung, 2014).In particular, a modified Cas9 protein (dead Cas9), which has an inactive endonuclease and so is not catalytically active, has allowed for the repression of gene expression. Dead Cas9 has been shown to interfere with DNA transcription and, when coupled with a guide RNA, is proven to be specific to its gene targets (Qiet al.,2013). However, unlike antisense RNA, the inhibition occurs pre-transcriptionally i.e. it interacts directly with the DNA rather than with the RNA. Dead Cas9 can be used to target the promoter region of a gene of interest using a guide RNA. Binding of the dead Cas9 protein to the promoter region hinders the binding of the RNA polymerase thus inhibiting the initiation of transcription.
More information
